At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 65 enrolled
Drug / intervention
MEDI4736 monotherapy +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Open-Label, Multi-Center Study of MEDI4736 Evaluated as Single Agent or in Combination With Tremelimumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
In Brief
A Phase 2 clinical trial evaluating MEDI4736 monotherapy and tremelimumab+MEDI4736 for Metastatic Pancreatic Ductal Adenocarcinoma. Completed, enrolled 65 participants across 21 sites in 6 countries.
Detailed Summary
A Phase II Open-Label, Multi-Center Study of MEDI4736 Evaluated as Single Agent or in Combination with Tremelimumab in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, Germany, Netherlands, South Korea, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 2015
Enrollment StartNov 2015
Primary CompletionJun 2017
TodayJul 2026
First PostedSep 24, 2015
Enrollment StartNov 16, 2015
Primary CompletionJun 15, 2017
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 10.8 years ago
Interventions
MEDI4736 monotherapydrug
MEDI4736 via IV infusion.
tremelimumab+MEDI4736drug
tremelimumab+MEDI4736 via IV infusion.